Charles River Laboratories (CRL) Tops Q2 EPS by 32c, Lifts Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/9/2026
- Wall St futures rebound as oil retreats, investors weigh US-Iran tensions
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Oil prices fall as markets weigh impact of US strikes on Iran
- Nvidia is up just 3% YTD while SOX surges 82% — what’s holding it back?
- BofA says S&P 500 technicals point to corrective Q3
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- GameStop stockholders approve share count increase to 2.5 billion
- Crude Inventory Rose 3 Million Barrels Last Week - EIA
- AI bubble fears mount as Zuckerberg admits agent delays and Burry shorts sector
- S&P 500 ends down after Trump says Iran deal is 'over'
Charles River Laboratories Announces Second-Quarter 2020 Results
August 5, 2020 7:00 AM EDTSecond-Quarter Revenue of $682.6 Million
Second-Quarter GAAP Earnings per Share of $1.34 and Non-GAAP Earnings per Share of $1.58
Increases 2020 Guidance
Announces Proposed Acquisition of Cellero in the High-Growth Cell Therapy Market
WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the second quarter of 2020. For the quarter, revenue was $682.6 million, an increase of 3.8% from $657.6 million in the second quarter of 2019.
Acquisitions contributed 3.2% to consolidated second-quarter revenue growth. The impact of... More
